1. CDC Grand Rounds: Public Health Strategies to Prevent Neonatal Abstinence Syndrome.
- Author
-
Ko JY, Wolicki S, Barfield WD, Patrick SW, Broussard CS, Yonkers KA, Naimon R, and Iskander J
- Subjects
- Centers for Disease Control and Prevention, U.S., Cost of Illness, Female, Health Knowledge, Attitudes, Practice, Humans, Infant, Newborn, Legislation as Topic, Neonatal Abstinence Syndrome epidemiology, Opioid-Related Disorders epidemiology, Opioid-Related Disorders prevention & control, Pregnancy, Prenatal Exposure Delayed Effects, United States epidemiology, Neonatal Abstinence Syndrome prevention & control, Public Health Practice
- Abstract
Neonatal abstinence syndrome (NAS) is a drug withdrawal syndrome that most commonly occurs in infants after in utero exposure to opioids, although other substances have also been associated with the syndrome (1). NAS usually appears within 48-72 hours of birth with a constellation of clinical signs, including central nervous system irritability (e.g., tremors), gastrointestinal dysfunction (e.g., feeding difficulties), and temperature instability (1) (Box 1). Opioid exposure during pregnancy might result from clinician-approved use of prescription opioids for pain relief; misuse or abuse of prescription opioids; illicit use (e.g., heroin); or medication-assisted treatment (MAT) of opioid use disorder (2) (Box 2).
- Published
- 2017
- Full Text
- View/download PDF